Clinical Trial Update: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating two administrations of COMP360 (psilocybin) for treatment-resistant depression, focusing on efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Depression

Drugs mentioned

• COMP360 (psilocybin)

Snippet

Sponsor: COMPASS Pathways | Conditions: Treatment Resistant Depression | Phase 3 | Status: ACTIVE_NOT_RECRUITING